Skip to main content

Vestronidase alfa Side Effects

Medically reviewed by Last updated on Oct 23, 2023.

Applies to vestronidase alfa: intravenous solution.


Intravenous route (Solution)

Anaphylaxis has occurred with vestronidase alfa-vjbk administration, as early as the first dose, therefore appropriate medical support should be readily available when vestronidase alfa-vjbk is administered. Closely observe patients during and for 60 minutes after vestronidase alfa-vjbk infusion. Immediately discontinue the vestronidase alfa-vjbk infusion if the patient experiences anaphylaxis.

Serious side effects of Vestronidase alfa

Along with its needed effects, vestronidase alfa may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking vestronidase alfa:


Incidence not known

Other side effects of Vestronidase alfa

Some side effects of vestronidase alfa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


For Healthcare Professionals

Applies to vestronidase alfa: intravenous solution.


The most frequently reported side effects were infusion site extravasation, diarrhea, rash, anaphylaxis, infusion site swelling, peripheral swelling, and pruritus.[Ref]


Very common (10% or more): Anti-drug antibodies developed (78%), neutralizing antibodies developed (55.6%), anaphylaxis (16.67%)[Ref]

Nervous system

Frequency not reported: Febrile convulsion[Ref]

A week 66 of treatment, 1 patient experiences a febrile convulsion during infusion of a 4 mg/kg dose. The infusion was stopped and the patient was given anticonvulsants, antipyretics, and antibiotics and the adverse reaction resolved. The patient was subsequently rechallenged without recurrence and continued on treatment with this drug.[Ref]


Very common (10% or more): Rash (25%)

Common (1% to 10%): Pruritus[Ref]


Very common (10% or more): Diarrhea (25%)[Ref]


Common (1% to 10%): Peripheral swelling[Ref]


Very common (10% or more): Infusion site extravasation (33.3%)

Common (1% to 10%): Infusion site swelling[Ref]


1. (2017) "Product Information. Mepsevii (vestronidase alfa)." Ultragenyx Pharmaceutical

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.